Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
- 3 April 2020
- journal article
- letter
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (8), 1378-1389
- https://doi.org/10.1002/ejhf.1793
Abstract
Aims We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death in patients with chronic heart failure (HF). We hypothesized that HK‐associated increased death may be related to RAASi withdrawal. Methods and results The ESC‐HFA‐EORP Heart Failure Long‐Term Registry was used. Among 9222 outpatients (HF with reduced ejection fraction: 60.6%, HF with mid‐range ejection fraction: 22.9%, HF with preserved ejection fraction: 16.5%) from 31 countries, 16.6% had HK (≥5.0 mmol/L) at baseline. Angiotensin‐converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) was used in 88.3%, a mineralocorticoid receptor antagonist (MRA) in 58.7%, or a combination in 53.2%; of these, at ≥50% of target dose in ACEi: 61.8%; ARB: 64.7%; and MRA: 90.3%. At a median follow‐up of 12.2 months, there were 789 deaths (8.6%). Both hypokalaemia and HK were independently associated with higher mortality, and ACEi/ARB prescription at baseline with lower mortality. MRA prescription was not retained in the model. In multivariable analyses, HK at baseline was independently associated with MRA non‐prescription at baseline and subsequent discontinuation. When considering subsequent discontinuation of RAASi (instead of baseline use), HK was no longer found associated with all‐cause deaths. Importantly, all RAASi (ACEi, ARB, or MRA) discontinuations were strongly associated with mortality. Conclusions In HF, hyper‐ and hypokalaemia were associated with mortality. However, when adjusting for RAASi discontinuation, HK was no longer associated with mortality, suggesting that HK may be a risk marker for RAASi discontinuation rather than a risk factor for worse outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health SystemHypertension, 2016
- Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012European Journal of Heart Failure, 2016
- Association between renin–angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort studyEuropean Heart Journal, 2015
- Underprescription of Renin–Angiotensin System Blockers in Moderate to Severe Chronic Kidney DiseaseThe American Journal of the Medical Sciences, 2015
- Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor AntagonistCirculation: Heart Failure, 2014
- Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term RegistryEuropean Journal of Heart Failure, 2013
- EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot)European Journal of Heart Failure, 2013
- Patient adherence to evidence‐based pharmacotherapy in systolic heart failure and the transition of follow‐up from specialized heart failure outpatient clinics to primary careEuropean Journal of Heart Failure, 2013
- A Simple Unified Approach for Estimating Natural Direct and Indirect EffectsAmerican Journal of Epidemiology, 2012
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011